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 BACKGROUND 
 Antiphospholipid syndrome (APS) or Hughes syndrome 
was ﬁ rst described in 1983 by Hughes. 1 
 Although only thrombotic phenomena and recurrent 
spontaneous abortion are included in the classiﬁ cation 
reviewed in 2006, 2 many other clinical features are known 
to be associated with APS. These include valvular heart 
disease, livedo reticularis, thrombocytopenia, nephropathy 
and speciﬁ c neurological manifestations. 3 The spectrum of 
clinical manifestations associated with APS, revealing itself 
as a complex entity, has contributed to the development 
of multiple clinical studies. The scientiﬁ c progress in the 
understanding APS’s pathophysiological mechanisms has 
provided new perspectives for a more effective therapeutic 
approach in these patients. 
 The current therapeutic guidelines are based on long 
time anticoagulation for secondary prevention after a ﬁ rst 
thrombotic episode. There is consensus in oral anticoagu-
lation with warfarin, in order to achieve an international 
normalised ratio (INR) target of between 2.0 and 3.0. 4 
 In patients with APS anticoagulated with warfarin and 
with thrombosis recurrence, the therapeutic approach 
currently advocated clearly shows that we are in need for 
new, safer and more efﬁ cacious treatment modalities. The 
authors describe a clinical report that reveals the diagnostic 
and therapeutic difﬁ culties related to this speciﬁ c group of 
patients. 
 CASE PRESENTATION 
 We describe a 60-year-old caucasian male patient with a 
known history of APS. The diagnosis was made 6 years 
earlier, after massive bilateral pulmonary thromboembo-
lism. Blood tests revealed elevated levels of antiphospholi-
pid autoantibodies in two determinations with 3-month 
intervals (positive lupus anticoagulant, anticardiolipin 
antibodies and β2 glycoprotein 1 (GPI)) and elevated 
inﬂ ammatory parameters (erythrocyte sedimentation rate 
(ESR) 35 mm/h and C reactive protein of 3.6 mg/dl). 
 An additional screening for thrombophilia was carried 
out, which was negative (Factor V Leiden variant, pro-
thrombin mutation, Factor VIII levels, methylenetetrahy-
drofolate reductase mutation, protein C, free and total 
protein S, factor VIII, antithrombin, plasminogen, tissue 
plasminogen activator plasminogen activator inhibitor 
and-1. 
 Since then, after resolution of the initial thrombotic 
event, he remained asymptomatic on warfarin anticoagu-
lation with a target INR between 2 and 3. 
 His personal history included Parkinson’s disease and 
benign prostatic hyperplasia, medicated. 
 The patient was seen in our department and subse-
quently hospitalised with pleuritic, left anterior chest pain, 
dyspnoea on moderate exertion and haemoptoic produc-
tive cough. He had these symptoms for about 1 week. No 
fever or constitutional symptoms were present. 
 On examination, the patient was afebrile and eupneic 
at rest. Cardiac and pulmonary auscultation revealed no 
abnormalities. Clinical examination was unremarkable. 
 INVESTIGATIONS 
 Blood tests showed an ESR of 55 mm/h and INR of 4.4, no 
anaemia or leukocytosis; Prostate-speciﬁ c antigen was in 
the normal range – 1.2 ng/ml. 
 A chest radiograph revealed a nodular lesion with 
3 cm in diameter, located in the middle lobe of left lung 
( ﬁ gure 1 ). 
 For clariﬁ cation of the radiological abnormalities, a lung 
CT scan was performed which showed a mass lesion with 
irregular contours, with extensive pleural deployment 
and bronchial involvement. CT scan images had changes 
imposing differential diagnosis with cancer, not excluding 
pulmonary infarction ( ﬁ gure 2 ). 
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 DIFFERENTIAL DIAGNOSIS 
 Considering the differential diagnosis of lung cancer and 
pulmonary infarction, a ventilation/perfusion scanning 
was performed and showed a high probability of pulmo-
nary embolism. 
 The patient also performed an echocardiogram that 
excluded right ventricular dysfunction. 
 Bronchoscopy showed no evidence of direct signs of 
malignancy. Histological examination was negative for 
neoplastic cells. 
 TREATMENT 
 Following the results obtained, the patient was treated 
with low-molecular-weiht-heparin in therapeutic dose 
despite having an INR value of 4.4, with progressive dis-
appearance of the initially abnormalities found on CT 
( ﬁ gure 3A,B ). 
 After resolution of acute episode, the patient was treated 
with high intensity warfarin medication, with an INR 
between 3 and 4. Treatment with statin was associated. 
 Some additional thrombotic risk factors were con-
trolled, namely, a sedentary lifestyle, overweight and 
hyperlipidaemia. 
 OUTCOME AND FOLLOW-UP 
 After 2 years of follow-up, the patient was diagnosed with 
prostate cancer, having undergone total prostatectomy. 
 Currently, he presents no symptoms and no recurrence 
of thrombosis. 
 DISCUSSION 
 The diagnosis of APS is considered when a clinical criterion 
– vascular thrombotic events or pregnancy morbidity – is 
associated with some speciﬁ c abnormal laboratory tests – 
analytical positivity for antiphospholipid antibodies. 5 In 
these patients the risk of arterial or venous thrombosis is 
increased, as well as its recurrence. 6 
 Several studies have shown that additional prothrom-
botic risk factors may be associated with an increased 
risk for thrombosis in patients with antiphospholipid 
antibodies. 7 A recent prospective study found that 50% of 
patients with APS had coincident risk factors for throm-
bosis at the time of a ﬁ rst thrombotic event. 8 Appropriate 
treatment of additional prothrombotic risk factors that can 
be modiﬁ ed in patients with antiphospholipid antibodies 
is essential to minimise the associated thrombotic risk. 
 A variety of risk factors have been identiﬁed to be linked 
to thrombotic events, including immobilisation during 
prolonged travel, obesity, smoking, surgery, trauma, oral 
contraceptives and postmenopausal hormone replacement. 
Medical conditions that increase the risk of thromboem-
bolism include cancer and APS. Some genetic risk factors, 
including factor V Leiden and the prothrombin G20210A 
mutation, have been identiﬁed, but they account for only a 
minority of thromboembolic disease. 9 
 As a result of the prothrombotic state in APS, anticoagu-
lation medication has been logically the mainstay of the 
treatment of this disease. However, some dilemmas exist 
regarding the optimal management of the different catego-
ries of APS patients. 
 The therapeutic approach after a ﬁ rst thrombotic episode 
is based on long-term anticoagulation, including oral anti-
coagulation with moderate-intensity warfarin to achieve 
target INR of 2.5. The duration of anticoagulant therapy 
should be decided on an individual basis, according to a 
multi-factorial risk assessment. 10 Current recommenda-
tions from the American College of Chest Physicians 
(ACCP) for treatment of patients with APS after an epi-
sode of venous thrombosis is anticoagulation with warfa-
rin with target INR value of 2.5 (level 1A) for 12 months 
(level 1C +). It should also be considered for indeﬁ nite anti-
coagulation (level 2C). 4 
 The authors present a clinical report where, despite the 
long-term anticoagulant therapy, with values above rec-
ommendations, new thrombosis occurred 6 years after 
beginning treatment with warfarin. They reported that 
the patient was diagnosed with pulmonary infarction, 
had an INR of 4.4, and thus is included in the minority 
of patients in whom thrombotic events recur despite ade-
quate anticoagulation. 
 Figure 1  Chest radiograph revealing a nodular lesion located in 
the middle lobe of left lung. 
 Figure 2  Lung CT scan images showing a mass lesion with 
irregular contours with extensive pleural deployment and 
bronchial involvement. 
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 The acute thrombotic episode was resolved with low-
molecular-weight-heparin in accordance with ACCP 
recommendations for the initial treatment of pulmonary 
embolism (level 1A). 4 In addition to the therapeutic recom-
mendations, the use of heparin can avoid the inherent var-
iations of INR associated to warfarin, ensuring adequate 
anticoagulation since the beginning of treatment. 
 The optimal treatment of thrombosis in patients with 
APS requires assessment of thrombosis risk associated with 
antiphospholipid antibodies so that the potential beneﬁ ts 
of antithrombotic therapies for preventing thrombosis can 
be balanced against the risk of bleeding. 6 
 With respect to the intensity of anticoagulation, sev-
eral retrospective studies ﬁ nd few or no recurrences when 
INR is over 3. Anticoagulation with an INR over 3 should 
be reserved for those cases in which venous thrombosis 
recurrence has occurred while under an INR between 2 
and 3. 11 
 British society of Haematology recommends an INR 
target of 2.5 for patients with venous thrombosis asso-
ciated to APS. A higher target of 3.5 is often used and is 
considered reasonable as long as the bleeding risk at the 
higher intensity of anticoagulation is taken into considera-
tion. A target of 3.5 is also recommended for patients who 
suffer recurrence of VTE while on warfarin with an INR 
between 2.0 and 3.0. 12 
 The fact that the patient experiences at thrombotic diag-
nosis an INR of 4.4 does not necessarily mean that pulmo-
nary infarction occurred at this INR value, given that the 
onset of symptoms was 1 week before. So, our option was 
to maintain this patient on warfarin, but with higher target 
INR, controlling the bleeding risk. Additional thrombotic 
risk factors were also eliminated. 
 Factors that may increase the risk of haemorrhage dur-
ing oral anticoagulant therapy include age greater than 65 
to 75 years, receiving multiple medications, history of gas-
trointestinal tract bleeding, arterial thrombosis or stroke 
and INRs higher than 4.5 to 5.0. 13 The described patient 
did not have any of these bleeding risk factors. 
 The prostate cancer only diagnosed 2 years later could 
be another thrombosis risk factor in this patient. 
 Some studies have shown a minimal likelihood of recur-
rence of thrombotic events in patients with APS, under 
moderate intensity treatment with warfarin (with an INR 
between 2 and 3). Derksen  et al reported a zero probability 
of thrombotic recurrence after 8 years of oral anticoagula-
tion maintained. 14 In the study published by Khamashta 
 et al , only 10% of patients with APS anticoagulant therapy 
with warfarin in therapeutic INR values of 3, had recurrent 
arterial or venous thrombotic events over 5 years. 15 
 The lack of precise guidelines hampers treatment of 
these patients uncertain and challenging. 
 Two recent randomised studies (Crowther  et al and 
Finazzi  et al ) comparing different intensities of anticoagu-
lation (a target INR of 2.5 comparing to a target higher than 
3.0) concluded that a target INR of 2.5 was sufﬁcient for 
treatment of patients with thrombosis in association with 
APS. 16  17 
 Besides lack of evidence-based data, some interna-
tional guidelines accept that the therapeutic strategy in 
patients with recurrent thrombosis while on warfarin, 
could be based on a higher target INR (between 2.5–3.5 
or 3.0–4.0). 12 
 Other possible treatment options for recurrent throm-
bosis despite warfarin are switching from warfarin to 
therapeutic doses of unfractionated heparin or low-molec-
ular-weight heparin, or adding an antiplatelet agent to war-
farin. 6 Dabigatran etexilate, a direct thrombin inhibitor, 
and rivaroxaban, the ﬁ rst in a new class of drugs, the oral 
direct factor Xa (FXa) inhibitors, are both ﬁ xed-dose orally 
administered agents and may be potential drugs in APS 
thrombosis treatment. 18 Plasma exchange or intravenous 
immune globulin, particularly in patients with catastrophic 
APS, has also been suggested. 6 
 Especially in secondary APS cases, associated with 
another autoimmune disease, an immunomodulatory 
strategy could be considered. Immunomodulatory thera-
pies that have been anecdotally used in patients with APS 
include steroids, cyclophosphamide and rituximab but 
these are generally used in combination with an aggressive 
antithrombotic strategy. 19 
 Recently, major advances in understanding the patho-
physiology of this syndrome have been made. The 
achievements in insight of the disease have opened the 
 Figure 3  (A, B) Lung CT scan images showing disappearance of 
the inicial lesion, after treatment with heparin in therapeutic dose. 
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door to the possibility of new more targeted therapeutic 
options that might be safer and more efﬁcacious than the 
standard treatment modalities. 20 In this context, potential 
targeted therapeutic approaches have been proposed with 
promising results, including for example, hydroxychloro-
quine, statins, inhibition of β(2) GPI and/or anti-β(2) GPI 
binding to target cells, complement inhibition, and B cell 
inhibition. 21 
 In conclusion, the diagnosis and treatment of a recurrent 
thromboembolic event in a patient with APS, adequately 
anticoagulated may not be linear. 
 We believe that the scientiﬁ c advances in understanding 
the mechanisms of antiphospholipid antibody-mediated 
thrombosis are driving us to a potentially new immuno-
suppressive combined approach. New therapeutic strate-
gies have been proposed, showing that much more can be 
done in the near future. 
 Learning points 
 ▶  The diagnosis and treatment of a recurrent 
thromboembolic event in a patient with APS, 
adequately anticoagulated may not be linear. 
 The recurrence of thrombotic events affects only  ▶
a minority of patients with APS, despite adequate 
anticoagulation. 
 Additional thrombosis risk factors should be controlled  ▶
and prevented in patients with APS. 
 Especially in secondary APS cases, associated with  ▶
another autoimmune disease, an immunomodulatory 
therapeutic strategy could be considered, beyond 
anticoagulation. 
 Competing interests  None. 
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